Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

Abstract Background Iron-deficiency anemia is common in inflammatory bowel disease, requiring oral or intravenous iron replacement therapy. Treatment with standard oral irons is limited by poor absorption and gastrointestinal toxicity. Ferric maltol is an oral iron designed for improved absorption a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2022-03, Vol.28 (3), p.373-384
Hauptverfasser:	Howaldt, Stefanie, Domènech, Eugeni, Martinez, Nicholas, Schmidt, Carsten, Bokemeyer, Bernd
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Administration, Oral Adult Anemia, Iron-Deficiency - drug therapy Clinical Research Female Ferric Compounds - administration & dosage Ferric Compounds - adverse effects Hemoglobins Humans Inflammatory Bowel Diseases - drug therapy Male Maltose - administration & dosage Maltose - adverse effects Maltose - analogs & derivatives Pyrones - administration & dosage Pyrones - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Background Iron-deficiency anemia is common in inflammatory bowel disease, requiring oral or intravenous iron replacement therapy. Treatment with standard oral irons is limited by poor absorption and gastrointestinal toxicity. Ferric maltol is an oral iron designed for improved absorption and tolerability. Methods In this open-label, phase 3b trial (EudraCT 2015-002496-26 and NCT02680756), adults with nonseverely active inflammatory bowel disease and iron-deficiency anemia (hemoglobin, 8.0-11.0/12.0 g/dL [women/men]; ferritin,
ISSN:	1078-0998 1536-4844
DOI:	10.1093/ibd/izab073